News

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...

May 15, 2012 – St. Jude Medical Inc., a global medical device company, announced CE mark approval and launch of its EnligHTN renal denervation system during EuroPCR. Renal denervation is a...

May 15, 2012 — Reaching out to patients with a few simple phone calls significantly improves the likelihood they’ll continue to take critically important medication that...

May 9, 2012 — Sound Interventions Inc. announced the successful completion of the company's first-in-human clinical trial to treat resistant hypertension, SOUND-ITV.

May 4, 2012 - Medtronic Inc. announced six-month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal...

May 2, 2012 — Vessix Vascular Inc. announced this week that it has received CE mark approval for its V2 Renal Denervation System for the treatment of hypertension. Renal denervation is a...

April 24, 2012—Providing more guidance to clinicians on the provision of optimal patient care, the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and American...

April 19, 2012 — Spherix Inc. announced results from its recently completed studies using near-infrared spectroscopy on autopsy samples from humans who had confirmed cardiovascular disease....

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

It seems a picture is worth more than a thousand words for people who see evidence of coronary artery disease, the most common type of heart disease in men and women. Simply seeing a build-up of...

Internet-based telemedicine systems appear to lead to more appropriate and effective pharmacotherapy, better blood pressure control and an overall reduction in cardiovascular risk compared to...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...

March 29, 2012 — A three-pronged intervention in Brazilian public hospitals significantly improved physician adherence to evidence-based protocols for treating acute coronary syndrome (ACS),...

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most...

March 19, 2012 – Individuals suffering from chronic heart failure (CHF) can look forward to the appearance of many new drug options over the next few years and place hope in a cure through future...

March 9, 2012 - Researchers say venom from the green mamba snake may aid in the preservation of cardiac and renal function following serious cardiovascular events, such as heart attack and acute...

March 8, 2012 — Transgenomic Inc. announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the company’s PGxPredict:...

March 7, 2012 — The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease...

February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

February 28, 2012 — Janssen Research and Development LLC announced that the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug...

February 23, 2012 — AstraZeneca announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a...

PARADISE

February 20, 2012 — ReCor Medical announced that its Paradise percutaneous ultrasound renal denervation system for achieving rhas received the CE mark. Paradise is designed to treat patients with...

February 20, 2012 — Biopharmaceutical company Celladon Corp. this week completed a $43 million equity financing to advance its lead investigational drug candidate Mydicar for the treatment of...

February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of...

February 15, 2012 — Medtronic Inc. announced the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across...

 

January 19, 2012 – New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor can achieve very fast blood thinning effects...

January 9, 2012 – Janssen Research and Development, LLC (JRD) announced today that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA)...

January 6, 2012 – A study led by researchers from the University of North Carolina at Chapel Hill School of Medicine has identified a molecular pathway that leads to this abnormal blood clotting...

January 5, 2011 – Bayer HealthCare's oral anticoagulant tablet Xarelto (rivaroxaban) has been approved for use in the United Kingdom in two important blood-clotting disorders

December 20, 2011 – The U.S. Food and Drug Administration (FDA) completed a safety review of the anti-arrhythmia drug Multaq (dronedarone). It showed an increased risk of serious cardiovascular...

December 5, 2011 – Roche announced that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading...

December 5, 2011 – The U.S. Food and Drug Administration (FDA) approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets).

November 17, 2011 — Westside Medical Imaging of Beverly Hills announces the availability of high resolution magnetic resonance imaging (MRI) with a 3 Tesla magnet to monitor the effects of...

November 18, 2011 – An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient (...

November 16, 2011 — Non-adherence to antiplatelet therapy – which prevents blood clots following percutaneous coronary intervention (PCI) – was associated with higher rates of both ischemic and...

November 16, 2011 – Johnson & Johnson Pharmaceutical Research & Development announced that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite...

November 15, 2011 — A clinical trial of patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and stable angina showed rapid genotyping followed by...

November 15, 2011 — A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was...

November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT)...

November 15, 2011 — Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who...

November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT conference in San Francisco. Patients with high platelet reactivity, as measured by...

November 9, 2011 – AstraZeneca announced that a combined expert committee of American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and Society for Cardiovascular...

November 9, 2011 — Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved Xarelto to reduce the risk of stroke and systemic embolism in patients with...

October 26, 2011 — Medtronic Inc. announced the start of SYMPLICITY HTN-3, the company’s United States clinical trial of the Symplicity Renal Denervation System for treatment-resistant...

October 24, 2011, — A new study demonstrates that angiotensin-converting enzyme (ACE) inhibitors taken in the first trimester of pregnancy pose no greater risk of birth defects than any other type...

October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next...

October 4, 2011 – Roche announced plans today to expand its coagulation testing product line in North America beyond physician offices and outpatient clinics with the development of a full line of...

September 28, 2011 — A clinical trial by Resverlogix Corp. is evaluating the early effects of a new drug compound in atherosclerotic plaque regression. The study is focused on patients with...

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular...

September 8, 2011 – A randomized multicenter, open-label study evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months'...

September 8, 2011 – Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the...

September 6, 2011 — The European Society of Cardiology (ESC) released the latest version of its guidelines for managing patients presenting without persistent ST-segment elevation. This version...

August 30, 2011 – Compared with patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence...

August 18, 2011 — The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated with 26 percent relative risk reduction in cardiovascular death, myocardial...

August 10, 2011 – The U.S. Food and Drug Administration (FDA) has approved Abbott’s RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries...

August 2, 2011 – The U.S. Food and Drug Administration recently cleared Abbott Vascular’s RX Herculink Elite Renal Stent System. The balloon-expandable, cobalt chromium, laser-cut stent is used to...

Aug. 2, 2011 — New York University (NYU) Langone Medical Center has received an $84 million grant from the National Heart, Lung and Blood Institute (NHLBI) to study the comparative effectiveness...

July 21, 2011 – The U.S. Food and Drug Administration (FDA) today approved AstraZeneca’s blood-thinning drug ticagrelor (Brilinta) to reduce cardiovascular death and heart attack in patients with...

July 14, 2011 — The U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the U.S. clinical trial of renal denervation with the Symplicity catheter...

July 5, 2011 — Janssen Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the...
June 30, 2011 — Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. announced today that two additional analyses from phase 3 studies of mipomersen were presented at the 79th European...
June 14, 2011 – New performance measures for adults with coronary artery disease (CAD) and hypertension were released today by the American College of Cardiology Foundation (ACCF), the American Heart...
June 10, 2011 – The U.S. Food and Drug Administration (FDA) announced safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose – 80 milligram (mg) –...
June 3, 2011 – European CE mark approval was granted to expand use of the VerifyNow point-of-care P2Y12 test platelet reactivity test to identify patients who are poor-responders to antiplatelet...
May 19, 2011 - Results from a study validating Cheetah Medical's noninvasive NICOM system specifically for use in patients with pulmonary hypertension were presented Wednesday, May 18th, at the 2011...
May 6, 2011 – A substance secreted by the heart that is associated with congestive heart failure and renal failure is not predictive of reduction in systolic blood pressure in patients treated with...

April 22, 2011 – A new study found that coronary artery bypass surgery added to medical therapy for selected chronic heart failure patients offered benefits over medical therapy alone.

April 21, 2011 – A new angiotensin II receptor blocker (ARB) has been approved by the U.S. Food and Drug Administration (FDA) to treat hypertension, or high blood pressure. Edarbi (azilsartan...

April 21, 2011 – Baxter International has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, a specialty pharmaceutical company based in King of Prussia, Penn....

April 7, 2011 – Primary results from the RADAR Phase 2b clinical trial were announced at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session. The trial looked at Regado...

April 7, 2011 – New study results have evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on clopidogrel (Plavix). The results showed that in healthy subjects,...

April 7, 2011 – Data from two phase 3 trials studying a drug for high-cholesterol patients who are on lipid-lowering therapy were presented at American College of Cardiology’s (ACC) 60th Annual...

April 1, 2011 – Oral antiplatelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing...